Teneobio

Teneobio was a privately held, clinical-stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), for the treatment of cancer, autoimmunity, and infectious diseases. Its TeneoSeek discovery platform combined genetically engineered animals (UniRat, OmniFlic), next-generation sequencing, bioinformatics, and high-throughput vector assembly. Teneobio was surfaced as a portfolio company of Lightspeed Venture Partners and added to the API Evangelist network as an enrichment lead. Amgen acquired Teneobio in October 2021 for $900 million upfront plus up to $1.6 billion in contingent milestone payments; the company no longer operates independently and publishes no live developer surface. This is a life-sciences / therapeutics company with no public API, developer portal, or machine-readable API artifacts.

Teneobio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Antibody Therapeutics, and Life Sciences.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyPharmaceuticalsAntibody TherapeuticsLife SciencesDrug DiscoveryOncology

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/teneobio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: teneobio
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/teneobio.png
name: Teneobio
description: Teneobio was a privately held, clinical-stage biotechnology company developing a new class of biologics, Human
  Heavy-Chain Antibodies (UniAb), for the treatment of cancer, autoimmunity, and infectious diseases. Its TeneoSeek discovery
  platform combined genetically engineered animals (UniRat, OmniFlic), next-generation sequencing, bioinformatics, and high-throughput
  vector assembly. Teneobio was surfaced as a portfolio company of Lightspeed Venture Partners and added to the API Evangelist
  network as an enrichment lead. Amgen acquired Teneobio in October 2021 for $900 million upfront plus up to $1.6 billion
  in contingent milestone payments; the company no longer operates independently and publishes no live developer surface.
  This is a life-sciences / therapeutics company with no public API, developer portal, or machine-readable API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/teneobio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- lightspeed-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: amgen
x-acquired-date: '2021-10-19'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Antibody Therapeutics
- Life Sciences
- Drug Discovery
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1